Wellness
September 24, 2026·5 min read
The conversation about GLP-1 receptor agonists has gotten loud. And in that noise, something important keeps getting skipped: who shouldn't be on these medications. GLP-1 contraindications aren't a footnote — for some people, they're the whole conversation. This post is about that.
GLP-1 receptor agonists are a class of medications that work by mimicking a gut hormone called GLP-1. They slow gastric emptying, reduce appetite signaling in the brain, and improve insulin sensitivity. Some newer medications add a second receptor mechanism, GIP, on top of that. They are tools, not transformations. They work alongside changes in nutrition, movement, sleep, and stress management, not instead of them.
At Enhance Aesthetics & Wellness, we offer medically supervised weight management. If prescription medication is part of someone's plan, the options are discussed at the consultation, after an individualized medical evaluation.
And before any of this conversation gets to dosing or titration, it starts with a screening evaluation. Because for a meaningful subset of people, the right answer is: GLP-1 therapy is not the right path.
Some contraindications to GLP-1 receptor agonists are absolute. These aren't clinical gray areas — they are hard stops, and the screening process is designed to catch them before treatment begins.
Medullary thyroid carcinoma (MTC) and MEN 2. The boxed warning in the FDA prescribing information for this medication class addresses the risk of thyroid C-cell tumors observed in rodent studies. Clients with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), should not take these medications. This is a non-negotiable contraindication. It is a labeled boxed warning, and our screening reflects that.
Pregnancy and breastfeeding. GLP-1 receptor agonists are not appropriate for pregnant or breastfeeding clients. Full stop. If you are pregnant, planning to become pregnant, or currently breastfeeding, this is not a conversation about whether GLP-1 therapy is right for you — it's a conversation about other approaches entirely.
These two categories are why we screen every client before moving forward. Not because we expect everyone to have these histories, but because the consequences of missing them are significant.
Beyond the absolute contraindications, there are clinical factors that require honest evaluation — not automatic disqualification, but a slower, more careful conversation.
History of pancreatitis. GLP-1 receptor agonists carry a known risk of pancreatitis. Clients with a history of acute or chronic pancreatitis require individual risk assessment. Research published in peer-reviewed literature has continued to examine this relationship, and our clinical evaluation includes a direct discussion of this history.
Gallbladder disease. Rapid weight loss — from any cause — can increase gallstone formation, and GLP-1 therapy is no exception. Clients with a history of gallbladder disease or gallstones should discuss this specifically. This isn't necessarily disqualifying, but it warrants informed discussion.
Severe gastrointestinal conditions. Because GLP-1 receptor agonists slow gastric emptying, clients with conditions affecting GI motility — including gastroparesis — may not be appropriate candidates, or may require specialized monitoring.
Concurrent medications. GLP-1 medications slow gastric emptying, which affects how other medications are absorbed. Clients on medications with narrow therapeutic windows, or on other agents that affect blood sugar, need to disclose their full medication list. This isn't a barrier — it's information that shapes how we approach the plan.
Eating disorder history. This is a clinical conversation that belongs in a careful evaluation. Appetite-suppressing medications interact with the psychology of eating in ways that require thoughtful assessment. We take this seriously, and it's part of our intake process.
Even for well-screened candidates, GLP-1 receptor agonists carry a risk profile that needs to be part of any informed consent conversation — not buried in fine print.
The most common side effects are gastrointestinal: nausea, vomiting, constipation, diarrhea, and abdominal discomfort. These are typically most significant during the early dose-titration period and often improve over time, but they are real and they affect some people significantly enough to discontinue.
Less commonly: hypoglycemia (especially relevant for clients on diabetes medications), severe gastrointestinal complications, and rare allergic reactions. The risk of gallbladder disease is real and worth discussing with any client who has a relevant history.
None of this means GLP-1 therapy is the wrong choice for the right candidate. It means the right candidate is someone who has had a thorough evaluation, understands the risks, and is being monitored by a clinician who is watching for them. Individual results vary significantly — weight-loss outcomes depend on dose, duration, baseline metabolic health, lifestyle factors, and individual response.
When someone comes to Enhance Aesthetics & Wellness asking about GLP-1 therapy, the first visit is a medical evaluation — not a sales conversation. Marina Roloff, DNP, FNP-C, performs the screening assessment, which includes a review of personal and family history, current medications, and relevant health history. If there are contraindications, we name them clearly and talk through alternatives. If the screening is clear, we discuss the program in detail — including dose titration, monitoring, and what realistic expectations look like for you specifically.
What we don't do: skip the screening to get to the prescription faster. The evaluation is the point. It's what makes the rest of the process responsible.
If you've been wondering whether GLP-1 therapy is right for you — or specifically whether it's not right for you — that question deserves a real answer, not a generic checklist. You can learn more about our medically supervised weight management programs or review what we offer in our weight loss injections program before scheduling. If you'd like to talk through your specific situation, I'd encourage you to schedule a consultation through our health and wellness services.
Call us at 928.370.4480 — or use the link above to get started.
Prescription and compounded treatments require a medical evaluation. Compounded medications are not FDA-approved. Individual results vary. Full disclosures.
Medically reviewed by Marina Roloff, DNP, FNP-C — 2026-09-24
Schedule a Consultation
Marina Roloff, DNP, FNP-C — Enhance Aesthetics & Wellness, Yuma, AZ
CONTACT US